EichorEICHOR
Condition: Platinum Resistant High Grade Epithelial Ovarian Cancer Synced from ClinicalTrials.gov · August 08, 2026

Recruiting studies: Platinum Resistant High Grade Epithelial Ovarian Cancer

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Assess Adverse Events and Change in Disease Activity in Participants With Platinum-Resistant Advanced High-Gr
Phase 2 · 52 location(s) · AbbVie · NCT06682988IN10018 in Combination With Standard Chemotherapy in High-grade Serous Epithelial Ovarian Cancer
Phase 1/Phase 2 · 7 location(s) · InxMed (Shanghai) Co., Ltd. · NCT05551507FiH Study to Investigate Safety, PK and Efficacy of the NaPi2b ADC TUB-040 in Patients With PROC or r/r Adenocarcinoma N
Phase 1/Phase 2 · 15 location(s) · Tubulis GmbH · NCT06303505Repurposing Atovaquone for the Treatment of Platinum-Resistant Ovarian Cancer
Phase 2 · 1 location(s) · Emory University · NCT05998135Testing the Combination of DS-8201a and Olaparib in HER2-Expressing Cancers With Expansion in Patients With Platinum Res
Phase 1 · 7 location(s) · National Cancer Institute (NCI) · NCT04585958First-in-Human Study of ATX-295, an Oral Inhibitor of KIF18A, in Patients With Advanced or Metastatic Solid Tumors, Incl
Phase 1 · 6 location(s) · Accent Therapeutics · NCT06799065A Study of Azenosertib (ZN-c3) in Subjects With Platinum-Resistant High-Grade Serous Ovarian, Fallopian Tube or Primary
Phase 2 · 92 location(s) · K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis P · NCT05128825Fuzuloparib Arsenic Trioxide Platinum Resistance Relapsed Ovarian Cancer
Phase 1/Phase 2 · 1 location(s) · Xing Xie · NCT04518501A Phase 2, Open-label, Single-arm Study Of Autologous M-CENK Adoptive Cell Therapy And N-803 (IL-15 Superagonist) In Com
Phase 2 · 2 location(s) · ImmunityBio, Inc. · NCT06710288Study to Assess GTAEXS617 in Participants With Advanced Solid Tumors
Phase 1/Phase 2 · 13 location(s) · Exscientia AI Ltd., a wholly owned subsidiary of Recursion P · NCT05985655Testing the Addition of Abemaciclib to Olaparib for Women With Recurrent Ovarian Cancer
Phase 1 · 27 location(s) · National Cancer Institute (NCI) · NCT04633239AZD5335 vs. Mirvetuximab Soravtansine in FRα-high and AZD5335 vs. Chemotherapy in FRα-low Platinum-resistant Ovarian Can
Phase 3 · 299 location(s) · AstraZeneca · NCT07218809Immunotherapy Platform Study in Platinum Resistant High Grade Serous Ovarian Cancer
Phase 2 · 6 location(s) · Canadian Cancer Trials Group · NCT04918186Efficacy & Safety of Olvi-Vec and Platinum-doublet + Bevacizumab Compared to Physician's Choice of Chemotherapy and Beva
Phase 3 · 32 location(s) · Genelux Corporation · NCT05281471A Study of Azenosertib (ZN-c3) Versus Investigator's Choice Chemotherapy in Subjects With Platinum-Resistant High-Grade
Phase 3 · 58 location(s) · K-Group, Beta, Inc., a wholly owned subsidiary of Zentalis P · NCT07546500Relacorilant in Combination With Different Treatment Regimens in Patients With Gynecological Cancers
Phase 2 · 49 location(s) · Corcept Therapeutics · NCT06906341A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, o
Phase 2/Phase 3 · 164 location(s) · Daiichi Sankyo · NCT06161025Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001)
Phase 1/Phase 2 · 66 location(s) · Genmab · NCT05579366
Look up another condition
Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →
Eichor
Clinical intelligence from public evidence
Use of Eichor is governed by our Terms of Use · Privacy Policy
© 2026 Biomedistats LLC (dba Eichor)

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.